Researchers have developed a diagnostic tool combining blood biomarker analysis and cognitive assessments to estimate the probability of Alzheimer's disease onset.

研究人員開發了一項診斷工具，結合血液生物標記分析與認知評估，用以估算罹患阿茲海默症的機率。

The methodology, detailed in Nature Communications, utilized a cohort of 174 participants who performed self-administered tests. The protocol integrates the measurement of p-tau217 and GFAP biomarkers via finger-prick blood samples with online cognitive evaluations. This dual-modality approach is intended to facilitate the prioritization of high-risk individuals for clinical intervention and diagnostic escalation. While the scalability of this cost-effective model is noted, further validation through diverse longitudinal studies is required.

該研究方法詳述於《自然-通訊》（Nature Communications），利用了 174 名參與者進行自我施測。該方案將透過指尖採血量測 p-tau217 與 GFAP 生物標記，與線上認知評估相結合。這種雙模態方法旨在協助將高風險個體優先安排臨床干預與進一步診斷。雖然此成本效益模型具有可擴展性，但仍需透過多樣化的縱向研究進一步驗證。

Regarding non-modifiable risk factors, Dr. Richard Oakley of the Alzheimer’s Society identifies advanced age as a primary determinant, noting that risk doubles approximately every five years after age 65 due to the aggregation of amyloid and tau proteins. Demographic data indicates a higher prevalence in women over 65, although the precise etiology—potentially involving hormonal or menopausal variables—remains under investigation. Genetic predisposition is also cited, specifically the APOE4 allele; however, the Alzheimer’s Society clarifies that familial mutations account for fewer than 10 per 10,000 cases, and the APOE gene serves as a risk enhancer rather than a definitive cause.

關於不可改變的風險因素，阿茲海默症協會的 Richard Oakley 博士將高齡列為主要決定因素，並指出 65 歲後由於類澱粉蛋白與 tau 蛋白的聚集，風險大約每五年增加一倍。人口數據顯示 65 歲以上女性的盛行率較高，儘管精確的病因（可能涉及荷爾蒙或更年期變數）仍在調查中。基因傾向也被提及，特別是 APOE4 等位基因；然而，阿茲海默症協會澄清，家族性突變在每萬例中不足 10 例，且 APOE 基因僅作為風險增強因子而非決定性原因。

Furthermore, the intersection of vascular health and cognitive decline is emphasized, as restrictions in cerebral blood flow can exacerbate protein-induced damage. Consequently, comorbidities such as hypertension, hypercholesterolemia, and diabetes are identified as significant risk factors. Conversely, the 2024 Lancet Commission report suggests that approximately 45% of dementia cases are attributable to modifiable factors. These include educational attainment, social engagement, and the management of metabolic and cardiovascular health. The report specifies that addressing 14 distinct lifestyle and health variables—ranging from hearing loss (7%) to physical inactivity (2%)—could potentially mitigate nearly half of global dementia occurrences.

此外，血管健康與認知能力下降的交集被重點強調，因為腦血流量受限會加劇蛋白質誘導的損害。因此，高血壓、高膽固醇血症與糖尿病等共病被確定為顯著風險因素。相反地，2024 年《柳葉刀》委員會報告指出，約 45% 的失智症個案可歸因於可改變的因素。這些因素包括教育程度、社交參與以及代謝與心血管健康的管理。報告指出，處理 14 個不同的生活方式與健康變數——從聽力損失 (7%) 到缺乏身體活動 (2%)——有可能減少全球近一半的失智症發生率。

The integration of home-based screening and the management of modifiable health factors represent the current strategic approach to reducing Alzheimer's risk.

整合居家篩檢與管理可改變的健康因素，代表了目前降低阿茲海默症風險的策略方法。